Rivero-Yeverino Daniela, Payan-Diaz Jonathan Higgins, López-García Aída Inés, Papaqui-Tapia José Sergio, Caballero-López Chrystopherson Gengyny, Ríos-López Juan Jesús, López-Romero Carlos David, Sánchez-Villalobos Johav Yael, Ortega Jordá-Rodríguez Elisa, Álvarez-Rivera Armando, Villada-Villada Erika
Servicio de Alergia e Inmunología Clínica, Hospital Universitario de Puebla, México.
Rev Alerg Mex. 2024 Jun 30;71(2):85-90. doi: 10.29262/ram.v71i2.1282.
To evaluate the impact of cholecalciferol (D₃) supplementation using clinical and paraclinical variables in patients with RA and vitamin D insufficiency and deficiency.
A randomized, double-blind, placebo-controlled study included patients from 5 to 40 years with a diagnosis of RA and vitamin D insufficiency and deficiency. They were supplemented for 8 weeks with 4000 or 5000 IU, depending on age. Total nasal symptoms score (TNSS) was measured monthly and 25(OH)D₃ levels at baseline and at the end of the study.
A total of 31 patients were included, with a mean age of 18.19 years. In the active group, there was a significant improvement in symptomatology with respect to the TNSS score and an increase in serum vitamin D levels (p < 0.01). There were no adverse reactions with cholecalciferol or placebo.
Supplementing patients with vitamin D₃, at the evaluated dose, together with conventional treatent for allergic rhinitis results in symptoms and quality of life improvement in patients with this disease.
使用临床和辅助临床变量评估补充胆钙化醇（D₃）对类风湿性关节炎（RA）合并维生素D不足和缺乏患者的影响。
一项随机、双盲、安慰剂对照研究纳入了年龄在5至40岁、诊断为RA且维生素D不足和缺乏的患者。根据年龄，他们接受了为期8周的4000或5000国际单位的补充。每月测量总鼻部症状评分（TNSS），并在基线和研究结束时测量25（OH）D₃水平。
共纳入31例患者，平均年龄为18.19岁。在活性药物组中，TNSS评分方面的症状有显著改善，血清维生素D水平升高（p < 0.01）。使用胆钙化醇或安慰剂均未出现不良反应。
对患者补充评估剂量的维生素D₃，并结合变应性鼻炎的常规治疗，可改善该病患者的症状和生活质量。
